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Abstract  
Receptor-interacting protein kinase (RIPK) 1 functions as a key mediator of tissue 
homeostasis via formation of Caspase-8 activating ripoptosome complexes, positively and 
negatively regulating apoptosis, necroptosis and inflammation. Here we report an 
unanticipated cell death- and inflammation-independent function of RIPK1 and Caspase-8, 
promoting faithful chromosome alignment in mitosis and, thereby, ensuring genome stability. 
We find that ripoptosome complexes progressively form as cells enter mitosis, peaking at 
metaphase and disassembling as cells exit mitosis. Genetic deletion and mitosis-specific 
inhibition of Ripk1 or Caspase-8 results in chromosome alignment defects, independently of 
MLKL. We found that Polo-like kinase 1 (PLK1) is recruited into mitotic ripoptosomes, where 
PLK1’s activity is controlled via RIPK1-dependent recruitment and Caspase-8-mediated 
cleavage. A fine balance of ripoptosome assembly is required as deregulated ripoptosome 
activity modulates PLK1-dependent phosphorylation of downstream effectors, such as 
BUBR1. Our data suggest that ripoptosome-mediated regulation of PLK1 contributes to 
faithful chromosome segregation during mitosis.  
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Introduction 
RIPK1 functions as critical signalling node in various innate immune pathways (Rickard et al., 
2014; Takahashi et al., 2014; Weinlich and Green, 2014). Its activity is subject to tight 
regulation, most notably by phosphorylation, ubiquitylation and Caspase-8 (Casp8)-mediated 
cleavage. Proper regulation of the kinase activity and scaffolding function of RIPK1 is crucial, 
as deregulation of RIPK1 is associated with various human pathologies (Silke et al., 2015).  
 
Following its activation, RIPK1 associates with the endopeptidase Casp8 and cellular FLICE-
like inhibitor protein (cFLIPL) through the adaptor molecule Fas-associated protein with Death 
Domain (FADD) to form a RIPK1-based Casp8 activating complex, variably referred to as 
complex-IIB (Petersen et al., 2007; Wang et al., 2008), ripoptosome (Tenev et al., 2011) or 
necrosome when the RIP kinase family member RIPK3 is also recruited to this complex 
(Pasparakis and Vandenabeele, 2015). For simplicity reason, we will subsequently refer to 
this RIPK1/FADD/Casp8/cFLIP multiprotein complex as ‘ripoptosome’. Formation of the 
ripoptosome frequently occurs under physiological conditions without killing the cell, 
generating a burst of sub-lethal caspase activity (Boatright et al., 2004; Micheau et al., 2002) 
that causes cleavage of RIPK1 and RIPK3 and destabilisation of ripoptosome complexes 
(Feng et al., 2007; Oberst et al., 2011). IAP-mediated ubiquitylation of RIPK1 and Casp8 
represents a further control point that restricts the lethal potential of RIPK1 and the 
ripoptosome (Tenev et al., 2011) 
 
Beyond its role in regulating cell death in some cell types, Casp8 also fulfils non-cell death 
functions (Maelfait and Beyaert, 2008). For example, evidence exists that indicate a possible 
tumour suppressor function of Casp8. Accordingly, deficiency of Casp8 facilitates cellular 
transformation in vitro (Krelin et al., 2008), acts as driver mutation in breast cancer (Stephens 
et al., 2012) and B-cell lymphoma (Hakem et al., 2012), and is frequently found to be mutated 
in hepatocellular carcinomas (Soung et al., 2005b) and advanced gastric cancer (Soung et al., 
2005a). Further, loss of Casp8 expression is associated with human neuroblastomas with N-
Myc amplification (Teitz et al., 2000), small-cell lung carcinoma (Hopkins-Donaldson et al., 
2003), and relapsed glioblastoma multiforme (Martinez et al., 2007). Moreover, Casp8 
reportedly is essential for maintaining chromosomal stability (Hakem et al., 2012), 
independent of its role in cell death. Despite these data, compelling evidence is lacking to 
support a direct causal role for Casp8 inactivation in the generation of cancer chromosomal 
instability.  
 
By studying why Casp8 is essential for maintaining chromosomal stability we identified RIPK1 
and Casp8 (ripoptosome complexes) as negative regulators of polo-like kinase 1 (PLK1), a 
key kinase that regulates chromosomal segregation, spindle assembly checkpoint and 
maintenance of genomic integrity (Medema et al., 2011; Zitouni et al., 2014). We noticed that 
ripoptosome complexes form physiologically during mitosis and that active PLK1 is recruited 
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into these complexes by RIPK1. Upon its recruitment, PLK1 is cleaved at D457 by Casp8, 
similarly to other ripoptosome components. In the absence of Ripk1, active PLK1 
accumulates, resulting in excessive phosphorylation of BUBR1 and mitotic defects. 
Conversely, enhancing ripoptosome formation during mitosis suppresses the interaction of 
PLK1 with its substrate BUBR1, resulting in hypo-phosphorylation of BUBR1 and defects in 
chromosome congression and segregation. Collectively, our data demonstrate that 
deregulation of key ripoptosome components cause chromosomal instability, independently of 
their role in cell death and inflammation. Our data provide a likely explanation to why loss of 
Casp8 and low levels of Ripk1 can be driver mutations in certain types of cancer, leading to 
chromosome instability that may favour tumour evolution, heterogeneity, acquisition of drug 
resistance and heighten risk for tumour relapse. 
 
 
Results  
The ripoptosome assembles during physiological mitosis 
Immunoprecipitation of Casp8 from cells in different stages of the cell cycle revealed that 
RIPK1, FADD, Casp8 and cFLIP associated during mitosis of HT1080, primary MEFs and 
HT29 cells, suggesting that the ripoptosome can form during mitosis (Figure 1A, 1B and 1C, 
and S1A). To visualise ripoptosome complexes in their native state in intact cells, we utilised 
in situ proximity ligation assay (PLA) to detect RIPK1/Casp8 complexes (Orme et al., 2016). 
While ripoptosome formation was undetectable in G2, ripoptosome complexes steadily 
formed as cells entered mitosis (prophase), peaking at metaphase and declining as cells 
exited M-phase (Figure 1D). Although, TRADD can also activate Casp8 (Anderton et al., 2018; 
Wang et al., 2008) we found no evidence for TRADD/Casp8 complexes during mitosis (Figure 
1E). Additional PLA controls are provided in Figure S1B and S1C. 
 
Ripoptosome complexes also formed in M-phases of unperturbed, non-synchronised cells 
(Figure S1D), indicating that this complex transiently forms during normal mitosis. PLA 
analysis detected mitosis-specific association of RIPK3/FADD, RIPK3/RIPK1 and 
RIPK3/Casp8 in MEFs (Figure 1F) and HT29 cells (Figure 1G), and confirmed cFLIP/Casp8 
interactions in mitotic cells (Figure 1H and S1I). All antibodies were tested for PLA signal 
specificity (Figure S1E, S1F, S1G, S1H and S1I). Ripoptosome formation during mitosis also 
occurred in a panel of additional cell types implying that ripoptosome formation during mitosis 
is a general phenomenon (Figure 1I). Using 3D reconstruction, RIPK1/Casp8 complexes 
appeared to be distributed throughout the nucleoplasm, and not associated with the spindle, 
centrosomes or kinetochores of mitotic cells (Figure S1J), which was in agreement with 
RIPK1- and Casp8- staining during mitosis (Figure S1K). 
 
Consistent with the formation of an active ripoptosome in mitosis, cells in M-phase showed 
significantly higher levels of caspase activity than cells in other cell cycle phases (Figure 1J 
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and S1L). Mitotic caspase activity was Casp8- and RIPK1-dependent as RNAi-mediated 
depletion of Casp8, or treatment with the RIPK1 kinase inhibitor Nec-1, suppressed this 
caspase activity (Figure 1J and 1K). Similarly, expression of the viral Casp8 inhibitor CrmA, or 
treatment with the caspase inhibitor zVAD-FMK, also suppressed caspase activity in M-phase 
(Figure 1J and S1L). Despite measurable levels of caspase activity, mitotic cells remained 
fully viable (Figure S1M, and data not shown). Consistently, mitotic cells were ‘unprimed’ to 
die by a mitochondria-dependent form of apoptosis (Figure S1N). Further, RNAi-mediated 
depletion of cFLIP suppressed the caspase activity in M-phase, indicating the non-killing 
activity of this complex (Figure S1O). RNAi-mediated depletion of Tnfr1, Trail-r1/r2, and 
CD95/Fas did not prevent formation of Casp8/RIPK1 complexes (Figure S1P). Under the 
same condition, RNAi-mediated depletion of these death receptors suppressed cell death 
mediated by their respective ligands (Figure S1Q). Together these data indicate that 
RIPK1/FADD/Casp8/cFLIP form a complex during mitosis (mitotic ripoptosome), generating a 
pulse of sub-lethal caspase-8 activity that is dependent on cFLIP and RIPK1 kinase activity. 
 
 
PLK1 is recruited to RIPK1 and the ripoptosome 
To gain further insights into the mitotic ripoptosome, we undertook a proteomic-based 
approach using RIPK1 as affinity reagent. In addition to known interactors of RIPK1, the mass 
spectrometry experiment also identified PLK1 as a putative binding partner of RIPK1 (Figure 
S2A). Under the same conditions, PLK1 was not co-purified with GFP, LacZ, FADD, Casp8, 
and cFLIP (data not shown), implying that the identification of PLK1 is not due to nonspecific 
interaction.  
 
Reciprocal immunoprecipitation of endogenous RIPK1 and PLK1 from cells in different stages 
of the cell cycle revealed that PLK1 and RIPK1 associated during mitosis (Figure 2A). 
Immunoprecipitation of endogenous Casp8, RIPK1 and FADD from mitotic cells also co-
purified PLK1 along with other components of the ripoptosome (Figure 2B and 2C). No such 
interaction with PLK1 was observed outside of mitosis. While wild-type and the constitutively 
active form of PLK1 (PLK1-T210D) bound to RIPK1, the PBD domain of PLK1 in isolation 
failed to bind to RIPK1, suggesting that PLK1 binds to RIPK1 independently of PBD-mediated 
phospho-recognition (Figure 2D). Recruitment of PLK1 to ripoptosome complexes was strictly 
RIPK1 dependent as PLK1 failed to be co-purified by Casp8 in the absence of RIPK1 (Figure 
2E). Interestingly, both FADD and cFLIP associated with Casp8 independently of RIPK1, 
suggesting that RIPK1 does not nucleate/trigger this complex during mitosis. RIPK1 mutants, 
lacking the RHIM or DD domain, readily associated with PLK1 (Figure S2B), indicating that 
RIPK1 can bind to PLK1 independently of FADD, caspase-8 or RIPK3.  
 
The interaction between RIPK1 and PLK1 in mitosis was also detectable using PLA with 
antibodies against RIPK1 and total PLK1 or phospho-specific PLK1 (anti-PLK1-pT210) 
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(Figure S2C, S2D, S2E and S2F). Mitosis-specific interaction between RIPK1 and PLK1 as 
well as RIPK3 and PLK1 was also detected in HT29 and primary MEFs (Figure 2F and 2G), 
expanding this observation to additional cell types. RNAi-mediated depletion of Tnfr1, Trail-
r1/r2, and CD95/Fas did not interfere with the formation of PLK1/RIPK1 complexes (Figure 
S2G). Together, our data demonstrate that PLK1, RIPK1, RIPK3, FADD, cFLIPL and Casp8 
form ripoptosome complexes in mitosis.  
 
The ripoptosome restrains PLK1 in mitosis  
Casp8 can cleave RIPK1, RIPK3 and cFLIPL within ripoptosome complexes (Oberst et al., 
2011). Since PLK1 is also recruited to such complexes during mitosis, we tested whether 
Casp8 cleaves PLK1 in a RIPK1-dependent manner (Figure 3A). Using CDK1i-synchronised 
and released primary Ripk1tamIEC-KO intestinal organoids we noticed that RIPK1 and PLK1 
were readily cleaved (Figure 3B). PLK1 cleavage was RIPK1-dependent as conditional 
ablation of Ripk1 caused accumulation of full-length PLK1 while diminishing the cleaved form. 
Ripk1 deletion also resulted in enrichment of active PLK1 (PLK1-pT210). Similar results were 
observed in synchronised Mouse Dermal-Fibroblasts (MDFs) where expression of RIPK1 was 
ablated by CRISPR/Cas9 (Figure S3A). Depletion of Casp8 resulted in a stronger 
PLK1/RIPK1 PLA signal (Figure 3C), suggesting that Casp8 negatively regulates 
PLK1/RIPK1 interactions. 
  
To gain further insights on how Casp8 regulates PLK1, we mapped the Casp8 cleavage site 
of PLK1. To this end we purified N- or C-terminally HA-tagged PLK1 from cells (Figure S3B), 
and offered it to recombinant Casp8 in presence or absence of zVAD-fmk. This revealed the 
presence of a Casp8 cleavage site (Figure 3D-E). Mutagenesis of putative cleavage sites 
revealed that Casp8 cleaves PLK1 at D457, which is surface exposed and evolutionarily 
conserved from flies to human (Figure 3E-D and S3B). Together these data suggest that 
recruitment of PLK1 to ripoptosome complexes induces Casp8-mediated PLK1 cleavage in a 
RIPK1-dependent manner, and that active PLK1, similar to RIPK1, is regulated via Casp8-
mediated proteolysis. 
 
To further study how the activity and size of mitotic ripoptosome affects PLK1, we decided to 
utilise pharmacological compounds known to modulate the activity and formation of the 
ripoptosome (Figure S3C) (Silke and Meier, 2013; Tenev et al., 2011). Pharmacological 
inhibition of IAPs (via SMAC mimetics (SM)), like treatment with the caspase inhibitor QVD, 
resulted in an increase in ripoptosome formation during mitosis, which was accompanied with 
enhanced PLK1 recruitment (Figure 3F and 3G). Co-treatment with the RIPK1 inhibitor 
GSK’963 (Berger et al., 2015) (subsequently referred to as RIPK1i) normalised complex 
formation (Figure 3F and 3G). While treatment with SM or QVD diminished the recruitment of 
active PLK1 (pPLK1-T210) into ripoptosome complexes, co-treatment with RIPK1i normalised 
this interaction (Figure 3F,S3D, S3E, S3F and S3G). Interestingly, treatment with the RIPK1i 
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alone significantly reduced the association of RIPK1 and PLK1 to the complex, albeit it did not 
completely block their recruitment to Casp8 (Figure 3F). While the immunoprecipitation in 
Figure 3F appears to contradict the PLA-based results (Figure 3G), it should be noted that 
PLA only assesses whether RIPK1 is in proximity to Casp8 but cannot assess how many 
molecules of RIPK1 are in proximity to Casp8. Given that the same number of PLA-speckles 
is formed following release into DMSO and RIPK1i, but significantly more RIPK1 co-purifies 
with caspase-8 under IP/Western conditions, we conclude that the RIPK1 inhibitor 
suppresses the ‘chaining’ of RIPK1 within the mitotic ripoptosome but does not affect its 
nucleation. The significant reduction of PLK1 is in line with our observation that recruitment of 
PLK1 is dependent (and directly proportional) to the recruitment of RIPK1 (Figure 2E). 
Together our data are consistent with the notion that enhanced ripoptosome formation 
negatively impacts PLK1. 
 
The ripoptosome negatively regulates PLK1-mediated phosphorylation of its 
downstream substrates 
To test whether the ripoptosome negatively regulates PLK1-mediated phosphorylation of its 
downstream substrates, we monitored the phosphorylation status of BUBR1 (Elowe et al., 
2010). PLK1-mediated phosphorylation of BUBR1 is required for chromosome congression, 
and the bipolar spindle attachment that forms the metaphase plate (Suijkerbuijk et al., 2012). 
We noticed that treatment with SM and QVD caused a dramatic loss of BUBR1 
phosphorylation at T680 (Figure 4A, and S4A-B). SM and QVD reduced phosphorylation at 
T680 of BUBR1 to a similar extent as treatment with PLK1i, or following Plk1 siRNA (Figure 
S4A and S4B). Importantly, co-treatment with RIPK1i normalised BUBR1 phosphorylation at 
T680 (Figure 4A, S4B). Consistent with reduced BUBR1 phosphorylation, we found that 
treatment with SM caused reduced binding of PLK1 to BUBR1 (Figure 4B). While treatment 
with SM reduced PLK1-BUBR1 interactions, co-treatment with RIPK1i restored the binding of 
PLK1 to BUBR1 to control levels. Similar results were obtained by PLA analysis (Figure 4C, 
4D, S4C and S4D). Since the levels of BUBR1 were unchanged following treatment with the 
respective inhibitors (or inhibitor combinations) (Figure 4A and S4C), our data suggest that 
deregulation of the ripoptosome interferes with PLK1-mediated interaction and 
phosphorylation of BUBR1. Consistently, we found that the level of BUBR1 phosphorylation 
was dramatically increased upon RNAi-mediated depletion of RIPK1 (Figure 4E and 4F). 
Although ripoptosome modulation affects PLK1-mediated phosphorylation of BUBR1, BUBR1 
is unlikely to be the only PLK1 substrate that is affected. This is because treatment with SM 
and QVD caused mis-localisation of PLK1 and abnormal mitosis (Figure 4G). Together, our 
data demonstrate that enhanced ripoptosome formation negatively impacts on PLK1’s ability 
to phosphorylate downstream substrates such as BUBR1.  
 
Acute pharmacological modulation of RIPK1 or Casp8 activity, specifically during 
mitosis, results in chromosome alignment defects 
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We next tested whether RIPK1-mediated deregulation of PLK1 results in mitosis defects. First, 
we evaluated mitotic timing via live cell imaging. While there was no significant difference in 
the length of mitosis of cells treated with DMSO, SM or SM/RIPK1i (Figure 5A and Suppl. 
movies),  careful analysis of individual frames revealed that SM-treated cells presented 
accumulation of chromosomal defects both during metaphase and/or anaphase (Figure 5B, 
5C, S5A, and Suppl. movies). Interestingly, these defects where completely rescued by co-
treatment with RIPK1i, which is in agreement with our observation that RIPK1i restores 
defects in BUBR1-pT680 phosphorylation upon SM treatment (Figure 4A, 4B, 4D, 4E, 4F, 4G).  
 
To gain further insights on the type of chromosomal abnormalities, we evaluated fixed mitotic 
cells released into media containing MG132, which allows accurate evaluation of 
chromosome segregation defects (Janssen et al., 2009) (Figure 5D). Microscopic images of 
mitotic HT1080 and RPE-1 cells, treated with SM, QVD, zVAD or RIPK1i, revealed a 
significantly higher number of chromosome alignment defects at the metaphase plate, and 
abnormalities at anaphase (Figure 5E, 5F, S5B, S5C, S5D, S5E and S5F). Importantly, the 
SM- and QVD/zVAD-mediated chromosomal abnormalities were fully rescued upon co-
treatment with two different RIPK1 kinase inhibitors, RIPK1i and Nec-1s (Figure 5E, 5F, S5C, 
S5D, S5E and S5F). In agreement with our data from HT1080 cells (Figure S5G), analysis of 
synchronised RPE-1 cells also showed that ripoptosome modulation caused the appearance 
of multipolar spindles (Figure S5H). This is consistent with a role of PLK1 in regulating Kizuna, 
TPX2, chTOG, TACC3 and clathrin (Maiato and Logarinho, 2014). Despite the abundance of 
such abnormalities, cells seemed to be able to complete mitosis (on average at the same 
time), however in some cases without achieving daughter cell separation. Nevertheless, this 
had significant consequences as treatment with SM, QVD, or RIPK1i led to a significant drop 
in clonogenic potential, which was restored upon co-treatment with the RIPK1 inhibitors 
RIPK1i and Nec-1s (Figure 5G and S5I). No such effect was observed when cells were 
acutely (2 hrs) treated with these compounds outside of M-phase (Figure S5J). Together, 
these data strongly suggest that RIPK1 and Casp8 contribute to proper chromosome 
dynamics during mitosis, and that their deregulation can result in chromosome alignment 
defects.  
 
Cells from Ripk1 and Casp8 knockout animals exhibit chromosome alignment defects 
Next, we wished to characterize cells from available knockout animals to determine whether 
genetic deletion of ripoptosome components results in chromosome alignment defects. To 
this end we assessed chromosomal segregation defects in synchronised primary MEFs 
derived from WT, Casp8fl/fl RosaCreER (Casp8-/- MEFs were obtained following treatment with 
Tamoxifen), Ripk1-/-, Mlkl-/-, and Casp8/Mlkl double-knockout (DKO) mice using a blinded-
experimental design (Figure 6A, 6B and 6C). Knockout cell lines were validated functionally 
and via western blot (S6A, S6B, S6C, S6D, S6E). Our data showed that 63 % of Casp8-/- 
mitotic cells had chromosome segregation defects (Figure 6B). Importantly, co-deletion of 
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Mlkl did not rescue these defects as 64 % of Casp8/Mlkl DKO MEFs exhibited chromosome 
alignment defects (Figure 6B). This demonstrates that the alignment defects of primary 
Casp8-/- MEFs occur independently of the necroptotic programme. Intriguingly, similar to 
Casp8-/- MEFs, 66 % of primary Ripk1-/- MEFs displayed chromosome alignment defects 
(Figure 6C). Since Ripk1-/- and Casp8-/- cells exhibited comparable levels of chromosome 
alignment defects, these data suggest that RIPK1 and Casp8 together contribute to proper 
chromosome alignment. The observed chromosome alignment defects were also evident in 
conditional Ripk1tamIEC-KO intestinal organoids (Figure 6D, S6F, S6G, S6H, S6I and S6J), but 
were absent in EtOH treated WT organoids. Importantly, 4-OHT treated Cre control organoids 
also did not present any abnormalities, indicating that the observed chromosomal defects in 
Ripk1tamIEC-KO were due to the conditional deletion of RIPK1 (Figure 6D, S6G, S6H, S6I and 
S6J). Like genetic deletion, RNAi-mediated knockdown of Ripk1 or Casp8 also caused 
chromosome misalignment in primary MEFs and human HT1080 cells (Figure 6E, S6K, S6L, 
and data not shown). Knockdown efficiency was determined functionally (Figure S6K) and 
biochemically (Figure S6L). Interestingly, co-knockdown of Casp8 and Ripk1 rescued 
chromosome alignment defects in primary MEFs (Figure 6E), which is in agreement with our 
pharmacological study using QVD and RIPK1i.  Primary MEFs derived from Ripk1K45A knock-
in mice showed modest chromosome alignment defects compared to control. However these 
were numerically lower than those observed in Ripk1-/- (Figure 6F). 
 
Chromosome alignment defects were also apparent in tissue sections derived from Casp8-/- 
(64 %) (E10.5), Casp8/Mlkl DKO (50 %) (E13.5), Ripk1-/- (large intestine 78 %, liver 49 %, 
and skin 55 %) (E19.5), and Ripk1/Tnfr1 DKO (large intestine 64 %, liver 49 %, and skin 55 %) 
(E19.5), but were absent in tissue sections from Ripk1/Casp8 DKO (E19.5) embryos, or Mlkl-/- 
(E13.5) embryos (Figure 6G, 6H, and 6I). Together, this demonstrates that RIPK1 and Casp8 
are involved in regulating chromosome segregation, independently of their role in inhibiting 
necroptosis or inflammation. While 78 % of mitotic cells in the large intestine of Ripk1-/- 
embryos had chromosome segregation defects, co-deletion of Casp8 completely rescued the 
Ripk1-/- segregation defects at E19.5 (Figure 6I). In contrast, co-deletion of Tnfr1 did not 
rescue the alignment defects of Ripk1-/- animals, even though it did rescue caspase-3 
activation and apoptosis in the large intestine and liver (Figure S6M and (Rickard et al., 
2014)). This demonstrates that cell death and chromosome alignment defects can be 
uncoupled genetically, and provides further evidence for a non-cell death function of RIPK1 
and the ripoptosome in mitosis.  
 
Ripk1 mRNA levels correlate with aneuploidy in human cancers 
Chromosomal mis-segregation defects are known to induce aneuploidy, which in turn has 
been shown to correlate with tumour onset, progression but also therapeutic treatment 
(Bakhoum and Swanton, 2014). Recently, a score of aneuploidy was calculated for most 
tumour samples, accessible by The Cancer Genome Atlas (TCGA) (Taylor et al., 2018), 
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allowing to correlate gene expression to aneuploidy. Our results clearly indicate that low 
expression of RIPK1 mRNA is significantly associated with higher aneuploidy in breast, lung 
and colorectal carcinomas (Figure 7A, 7B and S7A). Our analysis excluded samples bearing 
TP53 mutations (Taylor et al., 2018) and copy number variations of the RIPK1 gene. Also, we 
utilised CENP-A (centromeric histone) and PLK1 as a positive controls (Taylor et al., 2018). 
As expected, tumours with high levels of CENP-A or PLK1 displayed higher aneuploidy 
(Figure 7C, S7C and S7B). Interestingly, a low ratio between normalised expression of RIPK1 
and PLK1 mRNA levels showed an association with higher aneuploidy (Figure 7D). Together, 
these data suggest that a combination of low RIPK1 and high PLK1 might be associated with 
chromosomal mis-segregation and long-term aneuploidy in human cancers. 
 
Discussion  
RIPK1 and caspasae-8 are key players in inflammation, cell death and the regulation of tissue 
homeostasis, positively and negatively regulating these processes depending on the cellular 
context (Pasparakis and Vandenabeele, 2015). Beyond their role in inflammation and cell 
death, we find that RIPK1 and Casp8 also play critical roles in mitosis.  
 
Several lines of evidence demonstrate that RIPK1 and Casp8 contribute to normal mitosis. 
First, in mouse and human the ripoptosome naturally forms during mitosis, peaking at 
metaphases and disassembling as cells exit M-phase. Consistently, mitotic cells harbour sub-
lethal levels of caspase activity that is dependent on RIPK1, Casp8 and cFLIP. Second, PLK1 
is incorporated into the ripoptosome specifically in mitosis, an observation that is consistent 
with previous reports demonstrating an interaction between PLK1 and Casp8 (Matthess et al., 
2014) and FADD (Jang et al., 2011). Like for RIPK1 and RIPK3, recruitment of PLK1 to the 
ripoptosome results in Casp8-mediated cleavage. Third, ripoptosome-mediated regulation of 
PLK1 fine-tunes the localisation and activity of PLK1. Downregulation and hyper-activation of 
ripoptosomes cause defects in PLK1 localisation, PLK1-BUBR1 interaction and loss of PLK1-
mediated phosphorylation of BUBR1 (and most likely other PLK1 substrates), resulting in 
mitotic defects. Fourth, genetic deficiency or mitosis-specific pharmacological inhibition of 
ripoptosome components causes severe chromosomal alignment defects. These defects 
occur independently of cell death or inflammation. This is evident as Casp8/Mlkl DKO mice 
still present chromosomal instability, despite rescuing necroptotic cell death. Likewise, 
Ripk1/Tnfr1 DKO animals, which are fully viable at E19.5, harbour significant levels of 
chromosome alignment defects in various tissues, in the absence of caspase-3 activation. 
Hyper-formation of mitotic ripoptosomes, following SM treatment, may inhibit PLK1 function 
possibly by a two-pronged mechanism: i) via proteolytic cleavage of PLK1 within ripoptosome 
complexes and ii) by recruitment of PLK1 into ripoptosome complexes and sequestration 
away from its substrates (graphic abstract). Together, this reduces the availability of active 
PLK1 to phosphorylate important downstream substrates required for chromosome alignment 
and congression. Consistent with a role of sequestration, Casp8 knockdown enhances the 
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recruitment of PLK1 to RIPK1. Conversely, loss of RIPK1 de-represses PLK1, leading to 
substrate hyper-phosphorylation. Our current model proposes that PLK1 is recruited into the 
ripoptosome complexes via RIPK1, and that RIPK1 negatively regulates PLK1. This 
interaction is further regulated by Casp8, which not only cleaves RIPK1 but also PLK1 at 
D457. The cleavage of RIPK1 is required to regulate the recruitment of PLK1 and keep its 
activity under tight regulation. Upon loss of Casp8 or IAP depletion the RIPK1-PLK1 
association is enhanced leading to sequestration and inactivation of PLK1, ultimately 
interfering with PLK1-mediated phosphorylation of BUBR1. Under this condition, deregulated 
RIPK1 might bind to PLK1 and sequester it away from the spindle or chromosomes. On the 
other hand, when RIPK1 is missing, Casp8-mediated cleavage of PLK1 is lost (Fig. 3B and 
S3A), leading to accumulation of active PLK1. However, this alone would not explain why co-
deletion of Ripk1/Casp8 normalises the chromosomal instability observed in absence of either 
Casp8 or RIPK1. It is possible that, in the absence of Ripk1, Casp8 might (indirectly) lead to 
PLK1 over activation, potentially by cleaving and inactivating a protein involved in PLK1 
regulation at the spindle. Hence, concomitant loss of both RIPK1 and Casp8 would not only 
prevent RIPK1 induced inhibition of PLK1 but also Casp8-mediated over-activation of PLK1, 
leaving levels of PLK1 intact.  
 
Mice with a Ripk1 kinase-dead knock-in-allele (Ripk1K45A) develop normally (Berger et al., 
2014), even though primary MEFs of such animals do have some chromosome alignment 
defect, albeit such defects are very modest when compared to Ripk1-/-. Similar chromosome 
alignment defects as well as aneuploidy are also seen in Bubr1-/+ mice, yet such mice are 
fertile and die of old age and present only splenomegaly and abnormal megakaryopoiesis 
(Baker et al., 2004; Kapanidou et al., 2015). The tumorigenic phenotype due to this lingering 
chromosomal instability is manifested only upon challenge with the drug azoxymethane (Dai 
et al., 2004). It is, therefore, possible that the moderate number of chromosomal defects 
observed in the Ripk1kd is tolerated by the animals without affecting survival or fertility. 
 
Intriguingly, the mitotic ripoptosome seems to differ from other situations where 
ripoptosome/complex-II/necrosome complexes are formed. While depletion of cIAPs, 
activation of cytokine or pattern recognition receptors results in RIPK1-driven formation of 
RIPK1/FADD/Casp8/cFLIP complexes, during mitosis the formation of this complex seems to 
be driven by either FADD or Casp8. This is evident as FADD/Casp8 complexes form 
independently of RIPK1. Further, while RIPK1 kinase inhibition blocks ‘canonical’ 
ripoptosome formation, treatment with RIPK1i only prevents chaining of RIPK1 onto the 
mitotic ripoptosome without affecting the nucleation/generation of the complex. This suggests 
an important difference between kinase activity of RIPK1 and scaffolding function of RIPK1, 
both equally important for the regulation of PLK1. This is especially highlighted by the fact 
that loss of RIPK1 kinase activity in animals only induces low levels of chromosomal 
instability, a phenotype somewhat intermediate to the loss of RIPK1. 
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Our findings that the ripoptosome contributes to mitosis are consistent with earlier reports 
demonstrating that Casp8 is essential for maintaining chromosome stability, suppressing B-
cell lymphomagenesis (Hakem et al., 2012), restraining oncogene-induced transformation 
(Krelin et al., 2008), acts as driver mutation in breast cancer (Stephens et al., 2012) and is 
frequently found to be mutated or lost in different cancer types (Hopkins-Donaldson et al., 
2003; Martinez et al., 2007; Soung et al., 2005b). This, together with our analysis that mRNA 
levels of RIPK1 are associated with aneuploidy in breast, lung and colon cancer strongly 
suggest that Casp8 and RIPK1-mediated regulation of PLK1 is required for the maintenance 
of chromosome stability, consequent aneuploidy and suppression of cancer (at least in the B-
cell lineage for Casp8). 
 
Our observations have important ramifications, as they may help to explain why Casp8 is 
frequently lost in several kinds of human tumours, including small cell lung carcinoma, 
neuroblastoma, hepatocellular carcinoma, and others. Interestingly, Casp8 deficiency occurs 
by multiple mechanisms, including hyper-methylation of regulatory regions in the Casp8 gene 
or (less frequently) from gene mutation, suggesting that it is a causal factor in the oncogenic 
transformation rather than a consequence of it. Consistently, our data suggest that loss of 
Casp8, and subsequent deregulation of RIPK1 would provide cells with evolvability 
(chromosomal instability) leading to establishment of cellular transformation and 
tumorigenesis. 
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Figure Legends: 
 
Figure 1 | The ripoptosome forms during normal mitosis.  
(A,B,C) Human HT1080 (A) MEFs (B) and HT29 (C) cells were synchronized and lysates 
from asynchronous or synchronised cells were immunoprecipitated with anti-Casp8 (HT1080) 
or anti-FADD (MEFs, HT29) antibodies. Immunoblot analysis using the indicated antibodies is 
shown. The synchronisation scheme and collection points are indicated above.   
(D) In situ PLA detection of RIPK1 and Casp8 in HT1080 cells. Green dots indicate PLA 
signals of RIPK1/Casp8 complexes. The panel on the right show quantifications of 
RIPK1/Casp8 PLA speckles (mean ±SD from three independent experiments). In each 
experiment 10 cells were counted for each mitotic stage. Scale bars: 10 µm. 
(E-G) In situ PLA detection using antibodies against the indicated proteins. Green dots 
indicate proximity signals of RIPK1/Casp8 or TRADD/Casp8 in HT1080 (E), RIPK3/FADD, 
RIPK3/RIPK1 or RIPK3/Casp8 in MEFs (F) or HT29 (G). Scale bars: 10 µm.  
(H) In situ PLA detection of cFLIP and Casp8 in HT1080 cells. Green dots indicate proximity 
signals between cFLIP and Casp8. Scale bars: 10 µm.  
(I) In situ PLA detection of RIPK1 and Casp8 in the indicated cell lines. Green dots indicate 
PLA signals of RIPK1/Casp8 complexes. Scale bars: 10 µm. 
(J-K) DEVDase caspase activity analysis using CDK1i-synchronised and released HT1080 
cells treated with the indicated conditions.  
 
 
Figure 2 | RIPK1 interacts with PLK1.  
(A) HT1080 cells were synchronized with CDK1i and released. Lysates from asynchronous or 
synchronised HT1080 cells were immunoprecipitated with anti-RIPK1 or anti-PLK1 antibodies. 
Immunoblot analysis using the indicated antibodies is shown.  
(B) HT1080 cells were synchronized with CDK1i and released. Lysates from asynchronous or 
synchronised HT1080 cells were immunoprecipitated with anti-Casp8 antibody. Immunoblot 
analysis using the indicated antibodies is shown.  
(C) Lysates from synchronised and released HT29 cells were immunoprecipitated with anti-
RIPK1 or anti-FADD antibodies. Immunoblot analysis using the indicated antibodies is shown.  
(D) The indicated constructs were co-expressed in HEK-293T cells. Myc-immunoprecipitation 
was performed and RIPK1 interaction was assessed via western blot.   
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(E) HT1080 cells were synchronized with CDK1i and released. Lysates from asynchronous or 
synchronised HT1080 cells were immunoprecipitated with anti-Casp8 antibody. Immunoblot 
analysis using the indicated antibodies is shown.   
(F) In situ PLA detection of PLK1/RIPK1 or PLK1/RIPK3 in CDK1i-synchronized and released 
HT29. Green dots indicate PLA speckles. Scale bars: 10 µm 
(G) In situ PLA detection of PLK1/RIPK1 or PLK1/RIPK3 in CDK1i-synchronized and released 
MEFs. Green dots indicate PLA speckles. Scale bars: 10 µm 
 
Figure 3 | RIPK1 negatively regulates PLK1.  
(A) Schematic representation of RIPK1- and Casp8-mediated regulation of PLK1. 
(B) Immunoblots of primary intestinal organoids from two Ripk1fl/fl,IEC-creERTM animals. 
Organoids were treated with ETOH (vehicle control) or 4-OHT, synchronized with CDK1i and 
released into media. Cells were lysed and analysed by immunoblotting with the indicated 
antibodies. 
 (C) In situ PLA detection of PLK1 and RIPK1 in HT1080 cells, following Casp8 or Plk1 siRNA. 
Green dots indicate PLA signals between PLK1 and RIPK1. Graph shows quantifications of 
RIPK1/PLK1 PLA speckles (mean ±SD). 15 cells were counted for each condition. Scale bars: 
10 µm. 
(D-E) In vitro cleavage assay. Purified HA-tagged PLK1 construct and recombinant Casp8 
were incubated for 1 h. Immunoblots analysis using the indicated antibodies is shown. 
 (F) HT1080 cells were synchronized with CDK1i and released in media containing the 
indicated drugs. Lysates from asynchronous or synchronised HT1080 cells were 
immunoprecipitated with anti-Casp8 antibody. Immunoblot analysis using the indicated 
antibodies is shown. 
 (G) In situ PLA detection of Casp8/RIPK1 in CDK1i-synchronised and released HT1080 cells 
treated with the indicated agents. Green dots indicate PLA speckles. Scale bars: 10 µm. 
 
Figure 4 | RIPK1 negatively regulates PLK1-mediated phosphorylation of BUBR1.  
(A) Scheme illustrating how mitotic ripoptosome interacts and modulates PLK1 and how 
pharmacological inhibition regulates such interaction and downstream substrate activation. 
Immunofluorescence analysis using anti-BUBR1 or anti-BUBR1-pT680 antibodies. HT1080 
cells were synchronised with CDK1i and released into media containing the indicated agents. 
Scale bars: 10 µm.  
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(B) HT1080 cells were synchronised with CDK1i and released. Lysates from asynchronous or 
synchronised HT1080 cells were immunoprecipitated with anti-PLK1 antibody. Immunoblot 
analysis using the indicated antibodies is shown.  
(C,D) In situ PLA detection of PLK1/BUBR1 (C) or PLK1/BUBR1-pT680 (D) in synchronised 
HT1080 cells, treated with the indicated agents. Scale bars: 10 µm. 
(E) Immunofluorescence analysis using anti-BUBR1-pT680 antibodies (under extraction 
conditions) in CDK1i-synchronised HT1080 (left) and HT29 (right) cells under the indicated 
RNAi conditions. Cells were released for 30 mins after which MG132 was added for 90 mins 
to arrest cells in metaphase. N.T indicates non-targeting RNAi Control oligos. Scale bars: 10 
µm. 
(F) Western blot analysis of phosphorylated BUBR1 following knockdown of Control (Ctrl), 
Ripk1 or Plk1 in CDK1i-synchronised and released HT1080 cells. 
(G) CDK1i-synchronised HT1080 cells were released into media containing the indicated 
agents. Cells were released for 30 mins after which MG132 was added for 90 mins to arrest 
cells in metaphase. Only cells presenting mitotic abnormalities were scored for PLK1 
localisation. Images show representative examples of PLK1 mis-localisation. Scale bars: 10 
µm. 
 
Figure 5 | Hyper-activation of RIPK1 induces chromosome mis-alignment.  
(A) Asynchronised HT1080 cells were pre-incubated for two hours with 10 nM SIR-DNA and 
then treated with the indicated compounds. Mitotic duration of HT1080 assessed by 
quantifying the time elapsed between nuclear envelope breakdown (NEBD) and anaphase 
onset following treatment with the indicated agents.  
(B) Mitotic abnormalities detected in cells imaged by advanced spinning disc confocal 
microscopy time lapse to determine mitotic timing. Graphs show the percentage of mitotic 
abnormalities recorded in 100 mitosis per condition. 
(C) Example of mitotic cells visualised during advance spinning confocal time lapse. Frames 
were acquired every 6 mins. 
(D) Scheme depicting experimental procedure for synchronisation and release of cells during 
mitosis in indicated drugs. Examples of chromosome alignment defects to illustrate the 
scoring system. Scale bars: 10 µm. 
(E,F) CDK1i-synchronised HT1080 (E) and RPE-1 (F) cells were released into media 
containing the indicated agents. For the analysis in metaphases, cells were released for 30 
mins after which MG132 was added for 90 mins to arrest cells in metaphase. Anaphases 
were scored after 2 hrs release. Graphs indicate the number (n) of mitosis scored from 3 
independent experiments. Statistical analysis was performed via the two-way Anova multiple 
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comparison analysis with *P<0.05, **P<0.01, ***P<0.001. Total amount of abnormalities was 
considered in determining statistical significance.  Scale bars: 10 µm. 
 (G) Long-term colony formation assay of CDK1i-synchronised HT1080 cells that were 
released into media containing the indicated drugs for 2 hrs. Mitotic cells were collected by 
shake off, washed and 1000 cells were re-plated for clonogenic assay in the absence of drug. 
Graphs show the mean ±SE of three independent experiments, normalised to control. Two-
way Anova multiple comparison analysis with *P<0.05, **P<0.01, ***P<0.001. 
 
 
Figure 6 | Cells from Ripk1 and Casp8 knockout animals harbour defects in 
chromosome alignment. 
 
(A) Grading of segregation defects.  
(B,C) Chromosome alignment defects of the indicated primary MEFs. Images show 
representative phenotypes. Cells were released for 30 mins after which 10 µM MG132 was 
added for 90 mins to arrest cells in metaphase. Graphs indicate the number (n) of mitosis 
scored from 3 independent experiments. Statistical analysis was performed via the two-way 
Anova multiple comparison analysis with *P<0.05, **P<0.01, ***P<0.001. Total amount of 
abnormalities was considered in determining statistical significance Scale bars: 10 µm. 
(D) Primary intestinal organoids from Ripk1fl/fl,IEC-creERTM animals. Organoids were treated with 
ETOH (vehicle control) or 4-OHT, synchronized with CDK1i, released into media, and scored 
for alignment defects. Cells were released for 30 mins after which 10 µM MG132 was added 
for 90 mins to arrest cells in metaphase. Graphs indicate the number (n) of mitosis scored 
from 3 independent experiments. Statistical analysis was performed via the two-way Anova 
multiple comparison analysis with *P<0.05, **P<0.01, ***P<0.001. Arrows indicate misaligned 
chromosomes. Total amount of abnormalities was considered in determining statistical 
significance Scale bars: 10 µm. 
(E) Chromosome alignment defects of the indicated primary MEFs following knockdown of 
indicated genes. Images show representative phenotypes. Cells were released for 30 mins 
after which 10 µM MG132 was added for 90 mins to arrest cells in metaphase. Graphs 
indicate the number (n) of mitosis scored from 3 independent experiments. Statistical analysis 
was performed via the two-way Anova multiple comparison analysis with *P<0.05, **P<0.01, 
***P<0.001. Total amount of abnormalities was considered in determining statistical 
significance Scale bars: 10 µm. 
(F) Chromosome alignment defects of the indicated primary MEFs following knockdown of 
indicated genes. Images show representative phenotypes. Cells were released for 30 mins 
after which 10 µM MG132 was added for 90 mins to arrest cells in metaphase. Graphs 
indicate the number (n) of mitosis scored from 3 independent experiments. Statistical analysis 
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was performed via the two-way Anova multiple comparison analysis with *P<0.05, **P<0.01, 
***P<0.001. Total amount of abnormalities was considered in determining statistical 
significance Scale bars: 10 µm. 
 
(G-I) Hemotoxylin and eosin stained sections of embryos of the indicated age and genotypes. 
Mitotic abnormalities were scored throughout the entire embryo (G-H) and the large intestine, 
liver and skin (I). The graph indicates the S.E. of mitotic abnormalities scored from three (G-H) 
and two embryos (I). Total amount of abnormalities was considered in determining statistical 
significance  
 
Figure 7 | Ripk1 mRNA levels correlate with aneuploidy in Human cancers  
(A-D) Bioinformatics analyses of aneuploidy scores in association with RIPK1 mRNA 
expression (A-B), PLK1 mRNA expression (C) or the normalised ratio of the two (D) in breast 
(A, C, D) and lung (B) cancer patients. BRCA: Breast Cancer; LUAD: Lung Adenocarcinoma. 
**: p<0.01; ***: p<0.001; ****p<0.0001. (A) n: 461; (B) n: 128; (C) n: 293; (D) n: 218. 
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STAR METHODS 
 
CONTACT FOR REGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Pascal Meier (p.meier@icr.ac.uk). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Experimental Model  
All animal procedures were conducted in accordance with the guidelines of The Walter and 
Eliza Hall Institute Animal Ethics Committee, UK home office in accordance with the revised 
(2013) Animals (Scientific Procedures) Act (ASPA) and the institutional guidelines of the UCL 
Cancer Institute, or European, national and institutional guidelines approved by the local 
government authorities of the Landesamt fuer Natur, Umwelt und Verbraucherschutz 
Nordrhein-Westfalen, Germany. 
 
Cell lines  
Cell lines were obtained from ATCC (American Type Culture Collection). HT1080, RPE-1, 
KYM1, MDA-MB-231, T47D, ZR75, primary MEFs (passage number 2), HEK293T, U20S 
were cultured in DMEM. Culture media were supplemented with 10 % fetal bovine serum 
(GIBCO), penicillin and streptomycin. Cells were cultured under 10 % CO2. 
 
METHODS DETAILS 
Isolation of Primary cells 
Primary Mouse Embryonic Fibroblasts (MEFs) were generated from E13.5 embryos. After 
removing the placenta, yolk sac, head and the dark red organs, embryos were finely minced 
and digested for 20 min in 0.25 % trypsin. Single cell suspension was then obtained by 
pipetting up and down the digested embryos. Mouse Dermal Fibroblasts (MDFs) were 
isolated as described in (Etemadi et al., 2015).  To generate Bone Marrow Derived 
Macrophages (BMDMs), bone marrow cells from tibia and femur of 2 month old mice were 
seeded in non-coated petri dishes and cultured for 6 days in Dulbecco’s modified Eagle 
medium + 10 % fetal bovine serum + 20 % (v/v) L929 mouse fibroblast conditioned medium. 
Keratinocytes were isolated as described in (Lichti et al., 2008). Splenocytes were isolated 
from 2 month old mice. Mouse spleens were mashed through a cell strainer into the petri dish 
using the plunger end of a syringe. Cells were then washed once in cold PBS and treated 
with 1X Red Blood Cell Lysis Buffer (BioLegend, Cat N 420301) for 5 min on ice. Cells were 
then washed again in PBS and counted.  
 
Isolation of primary intestinal organoids 
Small intestine crypts were isolated and grown as described previously (Dannappel et al., 
2014). Deletion of Ripk1 in organoid cultures from Ripk1fl/fl,IEC-creERTM (RIPK1tamIEC-KO) was 
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induced with 100 nM 4-OHT for 24 hrs.  Ripk1fl/fl,IEC-creERTM  treated with ETOH for the duration 
of 24 hrs were used as controls. To synchronize organoid cultures, cells were treated with 9 
µM CDK1i for 20 hrs, after which cells were released using 3x washes with media. 10 mins 
after release, organoid cultures were supplemented with 20 µM MG132 for 90 mins. 
Chromosome misalignment was assessed 48 hrs and 72 hrs after 4-OHT treatment. For 
western blot analysis: intestinal organoids were harvested, and passed through a 23 G 
syringe.  Cells were centrifuged at 10000 rpm for 5 mins. Pelleted organoids were 
resuspended in 80 µl RIPA buffer (20 mM HEPES, pH 7.6, 350 mM NaCl, 1 mM MgCl2, 0.5 
mM EDTA, 0.1 mM EGTA, 20 % glycerol) supplemented with protease and phosphatase 
inhibitor tablets (Roche).  
 
Reagents and Antibodies 
The following reagents were used: zVAD-FMK (10 µM, Apex Bio), QVD (10 µM, Apex Bio), 
SM-164 (100 nM, gift from Shaomeng Wang), GSK’963 (referred as RIPK1i, 100 nM, 
GlaxoSmithKline), Nec-1 (10 µM Merck), Nec-1s (10 µM Merck), RO-3306 (9 µM, Merck), 
Thymidine (Sigma), BIM peptide (Kind gift of Tony Letai), FLAG-hTNF (10 ng/ml, Enzo), 
MG132 (1-20 µM, as indicated per cell line, see below, SIGMA), Recombinant Casp8 (1U 
Enzo). The following antibodies were used for western blotting: α-RIPK1 (1:1000, BD 
Biosciences), α-HA (1:1000, Roche), α-PLK1 (1:1000, Bethyl Laboratories), α-PLK1-pT210 
(1:2000, AbCam), α-Cyclin B (1:1000, Cell Signaling), α-BUBR1 (1:1000, BD Bioscience), α-
BUBR1-pT680 (1:1000, Kind gift of Geert J.P.L Kops), α-BUBR1-pT676 (1:1000, Kind gift of 
Erich A. Nigg), α-pH-H3 (1:2000, Millipore), α-Casp8 (for WB - post IP, 1:5000, MBL), α-
Casp8 - for IP (7.5 µg/ml, C-20, Santa Cruz Biotechnology, α-FADD – for IP (7.5 µg/ml, Santa 
Cruz), α-FADD (1:1000 BD Biosciences), α-RIPK3 (1:1000 Proscience), α-RIPK3 (1:1000 
Novus Biological) α-cFLIP (1:1000, Enzo), α-Myc (1:1000, clone 9E10,SIGMA), α-HSP90 
(1:1000 Santa Cruz Biotechnology) . 
 
RNA Interference, Transfections 
 siRNAs were purchased from Qiagen and Dharmacon. siRNA sequence information can be 
obtained upon request. All siRNA assays were performed using a total of 50 nM – 100 nM of 
siRNA. Upon multiple siRNAs combination, each siRNA was used at 25 nM and control 
siRNA was utilised to balance siRNA concentrations. All siRNA transfections were performed 
using DharmaFECT4 transfection reagent (GE Healthcare) and Opti-MEM (Life Technologies) 
according to manufacturer’s protocol. All siRNA transfections were performed using retro 
transfection and left for 40 hrs from the time of transfection to induce knockdown. For over-
expression studies, 5 x 105 cells were plated, and the indicated constructs were transfected a 
day after according to the Genejuice transfection protocol (Merck Millipore). Cells were 
harvested 24 hrs after transfection. 
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For the generation of CRISPR cells.  Guide RNAs (gRNAs) were designed utilizing the 
website tool: www.crispor.tefor.net. Guide RNAs were cloned in pLC-mCherry vector, 
expressing Cas9. MDFs were seeded in a 6-well plate and transfected with 2 ug of CRISPR 
vector using Viromer yellow transfection reagent (Cambridge Bioscience) according to the 
manufacturer’s instructions. Three days later, cells were sorted using fluorescence-activated 
cell sorting (FACS), and single clones were isolated and screened for the deletion of RIPK1. 
Positive clones were characterized. Guide sequence utilized to delete RIPK1 is available 
upon request. 
 
Cell synchronisation 
 Cells were treated with 9 µM of CDK1i (RO-3306) for 20 hours. Inhibitor was washed out by 3 
washes using full media, and cells were released in media containing DMSO (Ctrl) or media 
containing the indicated drugs. Asynchronised cells: cells not treated with CDK1i; G2 
population: cells collected following 20 hrs treatment with CDK1i; mitotic population: cells 
collected by shake off after a 2 hrs release; non-M population: cells left at the bottom of the 
plate following mitotic shake off; G1 cells: cells collected 16 hrs after release. For the scoring 
of chromosome misalignment, cells were released into media containing either DMSO or the 
indicated drugs for 30 minutes. After 30 min, cells were treated with 1 µM MG132 (HT1080), 
10 µM MG132 (RPE-1 and primary MEFs) for 90 mins. The addition of MG132 was added to 
assess the misalignments at metaphase plate (Janssen et al., 2009; Potapova et al., 2006) 
Cells were then fixed and processed as indicated above. Organoids were plated and treated 
with 4-OHT for 24 hrs to allow deletion of Ripk1. 4-OHT was removed and cells were treated 
with CDK1i for 20 hrs. Following 3x washes with media, organoids were released into media 
for 10 mins. After 10 mins, cells were treated with 20 µM MG132 for 90 mins. Organoids were 
fixed for IF or lysed for western blotting. For the clonogenic assay, cells were synchronized 
with CDK1i for 20 hrs, and released into media containing either DMSO or the indicated drugs. 
30 mins following release, cells were treated with MG132 for 90 minutes. Mitotic cells were 
collected by shake off, counted, and re-plated in media containing no drugs. For the 
clonogenic assay of non-M populations, cells were synchronized with CDK1i for 20 hrs, then 
released into media for 16 hrs.  Subsequently, cells were treated for 2 hrs with the indicated 
drugs. 30 mins following treatment, media containing drugs was supplemented with MG132 
for an additional 90 mins. Cells were then trypsinised, counted, and re-plated for clonogenic 
growth in media containing no drugs.  
 
Histology 
 E19.5 embryos were fixed in 10 % neutral buffered formalin, paraffin embedded. E10.5 
embryos were fixed in methanol, and agarose embedded. Embryos were then sectioned for 
routine histology staining (H&E). Slides were visualized and scored with a X100 objective. For 
immunofluorescent staining paraffin sections were dewaxed, subjected to heat-induced 
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epitope retrieval with citrate buffer then blocked and permeabilised with 1% BSA and 0.3% 
Triton X-100 (for anti-CC3) or blocke in IFF buffer and permeabilised in 0.5% Triton X-100 (for 
anti-alpha Tubulin and DAPI). Images were taken using a DP72 microscope and cellSens 
Standard software (Olympus) for CC3 or with Zeiss LSM 710 for alpha Tubulin and DAPI. 
 
Immunofluorescence 
1x105 cells were plated on 13 mm glass cover slips (VWR) and retro-transfected with siRNA 
or treated as indicated. Cells were then fixed in 4 % PFA for 10 mins. Following 10 mins 
permeabilisation with 1x PBS, 0.5 % Triton X-100, cells were blocked for 1 hr in 1x PBS, 5 % 
BSA. Respective primary antibodies were diluted in 1x PBS, 1 % BSA overnight at 4 OC. 
These were: α-PLK1 (1:200 for PLA; 1:1000 for IF, for mouse PLA-Abcam 1:50), α-PLK1-
pT210 (1:200 for DuoLink; 1:2000 for IF), α-BUBR1 (1:50 PLA, 1:1000 IF), α-BUBR1-pT680 
(1:1000), α-BUBR1-pT676 (1:1000), α-FADD (1:50 for PLA), α- RIPK3 (1:50 PLA 1:1000 for 
IF), α-Casp8: C-20 (1:50 PLA, 1:1000 IF), for mouse PLA (Santa Cruz 1:50), α-cFLIP (1:50 
PLA), α-RIPK1 (1:50 PLA, 1:1000 IF), α-α-Tubulin (Serotec 1:1000, for cells), α-α-Tubulin-
488 (1:100, for organoids), DAPI (Invitrogen), α-human CREST serum (1:2000, kind gift from 
Stephan Geley) , α-Phalloidin-633 (Invitrogen). Primary antibodies were washed 3x with 1x 
PBS, 0.1 % Triton X-100 for 10 mins.  Secondary Alexa fluor-conjugated antibodies were 
diluted in 1x PBS, 1 % BSA, and incubated for 1 hr at room temperature. These were: donkey 
α-rat-488 (1:1000, Invitrogen), donkey α-rat-633 (1:1000, Biotium), goat α-human-555 
(1:1000, Invitrogen), goat α-rabbit-488 (1:1000, Invitrogen), donkey α-mouse-488 (1:1000, 
Biotium), goat α-rabbit-633 (1:1000, Invitrogen). Secondary antibodies were washed 3x with 
1x PBS, 0.1 % Triton X-100 for 10 mins. DAPI was added to one of the three washes. Each 
slide was then washed with sterile water and mounted using Prolong Gold anti-fade 
fluorescent mounting media (Invitrogen). Organoids were fixed with 4 % PFA for 1 hr at 37 OC. 
These were then washed 3x in 1x PBS, and permeabilised for 1 hr using 1x PBS, 0.5 % 
Triton X-100.  Cells were blocked for 2 hrs using IFF blocking buffer (1x PBS, 1 % BSA, 2 % 
FCS). Primary antibodies were diluted in IFF and left incubating overnight at 4 OC, and then 
washed 3x with 1x PBS, 0.1 % Triton X-100 for 30 mins. Secondary fluorescent alexa fluor-
conjugated antibodies were diluted in IFF buffer, left for 4 hrs at room temperature, and 
washed 3x with 1x PBS, 0.1 % Triton X-100 for 20 mins. DAPI was added to each of these 
washes. The organoids chambers were further washed once in 1x PBS and once in H2O.  
Stained slides and organoids were visualised using the LSM710 Zeiss microscope, objective 
40x or 63x Zeiss. Images were acquired by sequential scanning. 
 
Live cell imaging 
1x105 HT1080 cells were seeded into 12-well plates (Porvoir), equilibrated into Leibovitz 15 
(Life Technologies) medium supplemented with 10 % FBS, 100 u/ml penicillin, 100 µg/ml 
streptomycin. Cells were incubated with 10 nM SIR-DNA and after treatments with the 
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indicated drugs, cells were imaged every 6 mins by advanced spinning disc confocal 
microscopy (Zeiss Axio Observer Z1, CSU-W1 T2 Spinning Disk Confocal, 50µm Disk, 
Yokogama, Incubation from Oko laboratories with Temperature and Manual CO2 Control, 
Hamamatsu ORCA-Flash4.0 V2+ sCMOS Camera - USB3.0/30fps 1 with 82 % peak QE, 
cooled to -10ºC, 76. EC Plan-Neofluar 40x/0.75NA Objective, M27 1, working distance 0.71 
mm, LaserStack 640 nm 100 mW, 692-40 filter). Only mitotic figures occurring within the first 
5 hrs of acquisition were taken into consideration for the analysis. Stacks and frames were 
acquired by SlideBook™ 6 Software System for Marianas™. Movies were resolved by 
maximum projection and extracted as TIFF file and visualized by Image J. The mitotic 
duration was assessed by quantifying the time elapsing between nuclear 
envelope breakdown (NEBD) and anaphase onset. 	  
 
Dynamic BH3 profiling (DBP)  
Dynamic BH3 profiling was conducted as previously described (Ryan and Letai, 2013). Briefly, 
0.2, 0.6, 2, and 6 µM of BIM BH3 peptide solution was prepared in DTEB (300 mM Trehalose, 
10 mM HEPES-KOH [pH 7.7], 80 mM KCl, 1 mM EGTA, 1 mM EDTA, 0.1 % BSA, 5 mM 
succinate).  Cells were plated at a density of 5 x 105 cells per well of a 6-well plate. Following 
synchronization, cells were collected and resuspended in DTEB at a density of 2.67x106 (4x 
density). One volume of the cell suspension was added to one volume of a 4x dye solution (4 
µM JC-1, 40 µg/ml oligomycin, 0.02 % digitonin, 20 mM 2-mercaptoethanol in DTEB). The 
cell/dye solution was left at room temperature for 10 mins to allow permeabilisation and dye 
equilibration. The cell/dye mix was then incubated with BIM BH3 peptides, and the mixture 
placed into the Infinite M200 pro TECAN plate reader. The plate was shaken for 15 seconds 
and individual wells were read at 590 nm over 3 hrs, every 5 mins at 30 OC. The obtained 
values were plotted as Δ priming. The difference in priming was determined by calculating the 
area under curve obtained following treatment with DMSO (control) and FCCP (control) minus 
the area under the curve obtained following treatment with the individual peptide 
concentrations and FCCP. These differences where then plotted as ΔΨn relative fluorescent 
unit (RFU) measured at 590 nm and normalized to asynchronously growing cells. 
 
DNA Plasmids 
PLK1 cDNA constructs were purchased from ADDgene. All constructs used for transient 
transfection experiments were cloned into the pcDNA3 expression vector (Invitrogen) and 
sequence verified.  
 
Caspase activity assays (DEVDase) 
1x104 cells were plated in 96-well plates and retro siRNA transfection was performed for 40 
hrs. For the caspase activity assays during prolonged mitosis, cells were plated in 96-well 
plates and treated as indicated for the indicated time points. After treatment, medium was 
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removed and 20 µl of DISC lysis buffer (20 mM Tris-HCL pH 7.5, 150 mM NaCl, 2 mM EDTA, 
1 % Triton X-100, 10 % glycerol) was added to each well. Pellets were washed in 1x PBS and 
lysed in DISC lysis buffer. Plates were placed at -80 OC to aid cell lysis. Plates were thawed 
at room temperature for 15 mins, after which 180 µl DEVDase assay mix (20 mM Ac-DEVD-
AMC (Sigma), 1 mM DTT, 50 mM Tris pH 7.5, 150 mM NaCl, 0.1 % Triton X-100, and 5 % 
glycerol) was added to each well (NB: cell lysates were not cleared). The plates were 
wrapped in foil and the reaction was incubated at room temperature for up to 24 hrs. 
DEVDase activity was read at 380 nM excitation/460 nM emission. For Mitotic population, 
cells were collected by mitotic shake off, then centrifuged for 5 mins at 2000 rpm. These were 
then lysed in DISC lysis buffer. All the other samples were trypsinised and cells were 
collected by centrifugation for 5 mins at 2000 rpm as for the mitotic population. Following 
addition of lysis buffer, samples were incubated at -80 OC to aid cell lysis.  50 µl of each 
samples was added to a 24-well plate and 450 µl of DEVEase assay mix was added to each 
well. Caspase activity was then measured as indicated above. The remaining of these 
samples was boiled and protein amounts were quantified. These were then utilized to 
normalize the individual caspase activity of each sample.  
 
In vitro caspase cleavage assay 
Recombinant Casp8 (2 U) and/or PLK1 (1 µg) were incubated in caspase cleavage buffer (50 
mM HEPES, pH 7.2, 50 mM sodium chloride, 0.1 % CHAPS, 10 mM EDTA, 5 % Glycerol, 10 
mM DTT) for 1 and 2 hrs at 37 OC. Samples were then diluted in 2X sample buffer and 
analysed by western blotting. 
 
Cell Death assay (FACS) 
Cell mixtures were incubated with medium containing 1 µg/ml propidum iodide and analyzed 
by FACS using a plate reader. Data shown are from 5000-10000 cells per condition. For cell 
viability of parental and Bcl-2 overexpressing HT1080 cells were assessed using a high-
content imaging system (ImageXpress Micro-XL, Molecular Devices). Cells were plated in 96-
well thin bottom plates in triplicate wells, and treated as indicated. A 20x long distance 
objective was used to image 16 sites in each well. Values were averaged for the 16 sites for 
each well, and shown are the mean +/- SEM of 3 wells for each condition. Before imaging 
cells were loaded with 40 nM SYTOX Green nucleic acid stain (ThermoFisher Scientific), 1 
µg/mL Hoechst 33342 (Sigma) for 30 mins. The dyes were present during imaging. Images 
were analysed using the Multiwavelength Cell Scoring module of the MetaXpress software 
(Molecular Devices). Cells were identified based on Hoechst staining, then nuclear SYTOX 
Green intensity was scored to identify cells with permeabilised plasma-membrane (SYTOX 
positive cells). Scoring was based on the size of area above threshold, determined by intact, 
non-treated cells.  
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Clonogenic Assays 
1000 cells were left for approximately 10 days in medium. Cells were fixed in 4% PFA/PBS 
for 10 mins and stained with crystal violet/PBS for 20 mins. Colonies were counted and 
recorded using Image J.     
    
Immuno-Precipitation Assays 
Cells were lysed in DISC lysis buffer (20 mM Tris-HCL pH 7.5, 150 mM NaCl, 2 mM EDTA, 
1 % Triton X-100, 10 % glycerol) supplemented with protease and phosphatases inhibitors. 
Cell lysates were left in the -80 OC to aid cell lysis for 20 mins, then rotated at 4 OC until 
thawed. Cell lysates were collected by centrifugation at 4 OC at 14000 rpm for 15 mins. 20 µl 
of G agarose (SIGMA); 7.5 µl Casp8 antibody/mg protein lysate (Santa Cruz) or 5 µl of Myc 
antibody/mg of protein lysate, were rotated with cleared protein lysates overnight at 4 OC. 5x 
washes in wash buffer (1x PBS, 1 % Triton X-100, 1 mM EDTA, 5 % glycerol) were 
performed, and samples eluted by boiling for 5 mins in 60 µl of 2x SDS loading dye. 
 
Proximity Ligation Assay 
1x105 cells were plated on a 13 mm glass cover slip (VWR) and retro-transfected with siRNA 
as indicated. Cells were then synchronised as described above and fixed in 4% PFA for 10 
mins. Following 10 mins permeabilisation with 1x PBS, 0.5 % Triton X-100, cells were blocked 
for 1 hr in 1x PBS, 5 % BSA. Respective pair of primary antibodies were then added as 
indicated. Proximity ligation was performed according to the manufacturer’s instructions using 
the Duolink Detection Kit (Cambridge BioScience Ltd, Cambridge UK). Ligation and 
amplification reactions were carried out according to manufacturer’s instructions. Cy3 signal 
amplification was utilised for the assay. Following PLA, cells were immune-blocked with α-rat 
α-tubulin (Serotec) diluted in PBS 1% BSA for 1 hr. Following three washes with 1x PBS, 
0.1 % Triton X-100, slides were incubated with donkey α-rat alexa fluor-633 diluted in 1x PBS, 
1 % BSA for 1 hr. Secondary antibody was washed three time with 1x PBS, 0.1 % Triton X-
100, and stained with DAPI for 10 mins. Each slide was then washed with sterile water and 
mounted using Prolong Gold anti-fade fluorescent mounting media (Invitrogen) and left to air 
dry overnight.  Cells were examined with a confocal microscope (objective 40x, Zeiss LSM 
710).  
 
Mass Spectrometry  
Prior to mass spectrometry analysis of RIPK1 interactors, eluted protein complexes were 
digested with Trypsin and peptides were purified using C18 Microspin columns (Harvard 
Apparatus) according to the manufactures instruction. LC-MS/MS analysis was performed on 
a dual pressure LTQ-Orbitrap mass spectrometer (Thermo Scientific), which was connected 
to an electrospray ion source (Thermo Scientific). Peptide separation was carried out using 
an easy nano-LC systems (Proxeon Biosystems) equipped with an RP-HPLC column packed 
with C18 resin (Magic C18 AQ 3 µm; Michrom BioResources). A 0.3 µl/min linear gradient 
	   29 
from 96 % solvent A (0.15 % formic acid, 2 % acetonitrile) and 4 % solvent B (98 % 
acetonitrile, 0.15 % formic acid) to 40 % solvent B over 40 min. The data acquisition mode 
was set to obtain one high-resolution MS scan in the FT part of the mass spectrometer at a 
resolution of 60,000 FWHM followed by MS/MS scans in the linear ion trap of the 20 most 
intense ions. Raw files were converted to the mzXML format, and searched against the 
human swissprot protein database. Further data processing including SAINT was carried out 
as described previously (Choi et al., 2011). 
 
Cell cycle profile 
5x105 cells where plates in a six well plate. Cells were synchronised as described above. 
Following synchronisation and release in media containing the indicated drugs, cells were 
fixed in 70 % EtOH for 24 hrs, and stained with rabbit alexa fluor 488 (pH-H3) and propidium 
iodide (PI). 5000 Cells were then analysed via FACS, and percentage of different cell cycle 
stages were obtained. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Experimental procedure 
Each experiment was conducted at least three times to generate three biological repeats. For 
western blots, immunoprecipitations and IF experiment the most representative experiment is 
shown. Bar graphs for quantifications show the average of three independent experiments the 
SE and P value generated following two way anova multiple comparison test. No adjustments 
for multiple comparison was utilised. Number (n) of cell counted per experiment is noted for 
each experiment either in the legend or on the figure. 
 
Statistics 
Data shown represent the mean +/- SD or SEM, as indicated in the figure legends. Two-way 
Anova multiple comparison analysis was performed for all the data unless otherwise indicated 
using Prism6. *P<0.05 **P<0.01 ***P<0.001.  
 
Data and software availability  
Raw data have been deposited to Mendeley Data and are available at 
http://doi:10.17632/x8tvmp6rfb.1 
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Supplementary Information 
Supplementary Figures: 
 
 
 
Figure S1 related to Figure 1 | The ripoptosome forms during normal mitosis.  
Liccardi et al. 
 2 
(A) FACS analysis of the cell cycle profile of CDK1i-synchronised and released HT1080 cells. 
Cells were stained with PI for DNA content and with pH-H3 (alexa fluor 488) to detect mitotic 
cells. Graphs indicate the synchronisation procedure and the time of cell collections for FACS 
analysis. 
(B-D) In situ PLA detection of RIPK1 and Casp8 in HT1080 cells treated with the indicated 
conditions. Green dots indicate proximity signals between RIPK1 and Casp8 in 
asynchronously growing cells treated with zVAD or TNF/SM/zVAD (B), or CDK1i-
synchronised and released cells upon the indicated knockdown (C), or asynchronously 
growing cells (D). (Scale bars: 10 µm). 
(E-I) In situ PLA detection in HT29 (E-G, I) and Mouse dermal Fibroblasts (MDFs) (H) or 
CDK1i-synchronised and released cells upon the indicated knockdown. Green dots indicate 
proximity signals between RIPK1 and Casp8 (E) RIPK1 and human-specific RIPK3 (F) RIPK1 
and mouse-specific RIPK3 (H) human-specific RIPK3 and FADD (G) and Casp8 and c-FLIP (I) 
(Scale bars: 10 µm). 
(J) 3D-reconstruction (IMARIS) of ripoptosome complexes visualised by PLA.  
(K) Immunofluorescence analysis using anti-RIPK1 and anti-Casp8 antibodies. HT1080 cells 
were synchronised with CDK1i and released into media. Scale bars: 10 µm. 
(L) DEVDase caspase activity analysis using synchronised and released HT1080 cells in the 
presence or absence of CrmA. For this experiment, we used HT1080 that carry an inducible 
construct of CrmA (Tenev et al., 2011). The graph shows a representative experiment of 
three independent experiments.  
(M) Viability assay of CDK1i-synchronised and released HT1080 cells. The graph shows the 
mean ±SE of three independent experiments.  
(N) BH3 profile of CDK1i-synchronised and released HT1080 cells. Graphs show the mean 
±SD of three experiments. The differences in priming was plotted as DYn relative fluorescent 
unit (RFU) and normalized to asynchronously growing cells.  
(O) DEVDase caspase activity analysis using CDK1i-synchronised and released HT1080 
cells treated with the indicated conditions. 
(P) In situ PLA detection in CDK1i-synchronised and released HT1080 cells upon the 
indicated knockdown. Green dots indicate proximity signals between RIPK1 and Casp8 
(Scale bars: 10 µm). 
(Q) Functional validation of the knockdown efficiencies. Cell death assay of HT1080 
transfected with the indicated siRNA oligos following indicated treatment (24 hrs). Graphs 
show the mean ±SD of three independent experiments. Two-way Anova multiple comparison 
analysis with ***P<0.001 
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Figure S2 related to Figure 2 | RIPK1 interacts with PLK1.  
(A) Schematic representation of RIPK1-bound target proteins that were identified by mass 
spectrometry. The table specifies the sum of the unique peptides of the target protein 
identified.  
(B) The indicated constructs were co-expressed in HEK293T cells. HA-immunoprecipitation 
was performed and PLK1 interaction was assessed via Western blot. 
(C-D) In situ PLA detection in CDK1i-synchronised and released HT1080 cells. Green dots 
indicate proximity signals between RIPK1 and pPLK1-T210 (C) and RIPK1 and PLK1 (D) 
(Scale bars: 10 µm). 
(E-F) Immunofluorescence analysis using anti-PLK1 (E) and anti-PLK1-pT210 (F) antibodies 
using different fixation conditions. HT1080 cells were synchronised with CDK1i and released 
into media. Scale bars: 10 µm  
Liccardi et al. 
 4 
(G) In situ PLA detection in CDK1i-synchronised and released HT1080 cells upon the 
indicated knockdown. Green dots indicate proximity signals between RIPK1 and PLK1 (Scale 
bars: 10 µm).  
Liccardi et al. 
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Figure S3 related to Figure 3 | RIPK1 negatively regulates PLK1. 
(A) Immunoblots of mouse dermal fibroblasts where Ripk1 was ablated by CRISPR/Cas9. 
Cells were synchronized with CDK1i and released into media for 2 hours and then lysed and 
analysed by immunoblotting with the indicated antibodies 
(B) Schematic representation of the PLK1 constructs utilised in the in vitro cleavage assay. 
Alignment of Drosophila, Human and Mouse Plk1 sequence highlighting the identified 
cleavage site.  
(C) Schematic representation of RIPK1 regulation, and the drugs utilised to modulate RIPK1’s 
kinase and scaffolding function.  
(D) Synchronised HT1080 cells were released in media containing the indicated drugs. 
Lysates were immunoprecipitated with anti-Casp8 antibody. Immunoblot analysis using the 
indicated antibodies is shown. 
(E-G) In situ PLA detection of PLK1/RIPK1 (E) or PLK1-pT210/RIPK1 (F-G) in CDK1i-
synchronised and released HT1080 cells treated with the indicated agents. Green dots 
indicate PLA speckles. Scale bars: 10 µm. 
Liccardi et al. 
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Figure S4 related to Figure 4 | RIPK1 negatively regulates PLK1-mediated 
phosphorylation of BUBR1. 
(A-C) Immunofluorescence analysis using CREST serum, anti-BUBR1-pT680 and anti-
BUBR1 antibodies using different fixation conditions. HT1080 cells were synchronised with 
CDK1i and released into media. Scale bars: 10 µm. 
Liccardi et al. 
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(D) In situ PLA detection of PLK1 and BUBR1 in HT1080 cells, treated with the indicated 
agents. Green dots indicate proximity signals between PLK1 and BUBR1. Scale bars: 10 µm. 
 
 
 
Figure S5 related to Figure 5 | Hyper-activation of RIPK1 induces chromosome 
misalignment.  
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(A) Example of mitotic cells visualised during advance spinning confocal time lapse. 
Each frame was acquired every 6 mins. 
(B) Examples of chromosome alignment defects to illustrate the scoring system. Scale bars: 
10 µm. 
(C-F) CDK1i-synchronised HT1080 (B and C) and RPE-1 (D and E) cells were released into 
media containing the indicated agents. For the analysis in metaphases, cells were released 
for 30 mins after which MG132 was added for 90 mins to arrest cells in metaphase. 
Anaphases were scored after 2 hrs release. 100 mitosis were counted for each condition per 
experiment.  
(G) Example of mitotic cells visualised during advance spinning confocal time lapse. Each 
frame was acquired every 6 mins. 
(H) CDK1i-synchronised RPE-1 cells were released into media containing the indicated 
agents. For the analysis in metaphases cells were released for 30 mins after which MG132 
was added for 90 mins to arrest cells in metaphase. Anaphases and Multipolar mitosis were 
scored after 2 hrs release. Figure shows representative images of the collected phenotypes. 
Graphs show the mean ±SE of two independent experiments. Scale bars: 10 µm. 
(I) Synchronised HT1080 cells were released into media containing the indicated drugs for 30 
minutes and then treatment was supplemented with MG132 for 90 minutes. Mitotic cells were 
collected by shake off and 1000 cells were plated for clonogenic assay  
(J) CDK1i-synchronised HT1080 cells were release into media for 20 hrs and then released in 
media for 30 mins, after which cells were treated with MG132 for 90 minutes. 16 hrs following 
release cells were treated with the indicated drugs for 2 hrs. Cells were collected by 
trypsinisation, washed and the indicated number of cells were plated for clonogenic assay.  
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Figure S6 related to Figure 6 | Deficiency of RIPK1 or Casp8 results in chromosome 
alignment defects 
 (A) Grading of segregation defects. The scheme indicates the experimental procedure as 
detailed in material and methods.    
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(B-C) Functional validation of primary MEFs following treatment with SM/TNF (24 hrs). 
Genetic deletion is indicated. Graphs show the mean ±SD of three independent experiments. 
Two-way Anova multiple comparison analysis with ***P<0.001. 
(D-E) Western blot validation of primary MEFs with the indicated genetic deletions. 
(F) RIPK1 immunoblots of Ripk1tamIEC-KO-derived organoids treated with vehicle control (EtOH) 
or 4-OHT for 20 hrs. Organoid cultures were analysed at the indicated time points.  
(G-J) Images depict Ripk1tamIEC-KO-derived organoids treated with EtOH (G) or 4-OHT (H-J). 
Arrows indicate chromosomal misalignment. i,ii,iii and square indicate abnormal mitosis. 
Images show chromosomal abnormalities before and after loss of intestinal architecture. 
Scale bars: 10 µm. 
(K) Functional validation of the knockdown efficiencies. Cell death assay of primary MEFs 
transfected with the indicated siRNA oligos following treatment with SM/TNF (24 hrs). Graphs 
show the mean ±SD of three independent experiments. Two-way Anova multiple comparison 
analysis with ***P<0.001 
(L) Chromosome alignment defects of synchronised and released HT1080 cells in which the 
indicated genes were knocked-down by RNAi. Graphs show the mean ±SE of three 
independent experiments. Two-way Anova multiple comparison analysis with ***P<0.001. 
Total amount of abnormalities was considered in determining statistical significance. 
Levels of knockdown were validated by Western blot analysis. 
(M) Tissue sections of the indicated genotypes stained with cleaved caspase-3 (CC3) (brown) 
and hematoxylin (blue). Brown cells are positive for CC3. Black arrows indicate CC3 positive 
cells. 
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Figure S7 related to Figure 7 | RIPK1 mRNA levels correlate with aneuploidy in Human 
cancers  
(A-C) Bioinformatics analyses of aneuploidy scores in association with RIPK1 mRNA 
expression (A), CENP-A mRNA expression (B) and PLK1 mRNA expression (C) in colorectal 
(A), breast (B) and lung (C) cancer patients. COAD: Colorectal Adenocarcinoma; BRCA: 
Breast Cancer; LUAD: Lung Adenocarcinoma. **: p<0.01; ****p<0.0001. (A) n: 89; (B) n: 516; 
(C) n: 140. 
 
Supplementary items. Supplementary movies 1-3 related to Figure 5 | Modulation of 
RIPK1 induces Chromosomal instability.  
Asynchronised HT1080 cells were pre-incubated for two hours with 10 nM SIR-DNA and then 
treated with the indicated compounds: DMSO, SM, SM/RIPK1i. Live cell imaging was 
recorded by advance spinning confocal time lapse filming. Frames were acquired every 6 
mins for 10 hours. Only the first 5 hours (90 frames) were taken in consideration. Movies 
should be opened via ImageJ and colour balance should be adjusted according to the user 
preferences.  
 
 
